Alcohol Linked with Lobular Breast Cancer (09/03/2010)
Although alcohol is a well-established risk factor for breast cancer, it may be more strongly linked with lobular breast cancer than with ductal breast cancer. These results were published in the Journal of the National Cancer Institute.

Additional Research on Menopausal Hormone Therapy and Breast Cancer (08/24/2010)
A recent study of menopausal hormone therapy and risk of breast cancer reported that risk may vary by body weight and the type of hormone therapy. These results were published in Cancer Epidemiology, Biomarkers, & Prevention.

Mediterranean Diet May Lower Breast Cancer Risk (08/16/2010)
Postmenopausal women who consume a traditional Mediterranean diet may have a lower risk for breast cancer, according to a study published in the American Journal of Clinical Nutrition.

Study Evaluates Impact of Lymph Node Removal in Early-stage Breast Cancer (08/13/2010)
Early-stage breast cancer patients without evidence of cancer in their sentinel lymph node who did not have additional lymph nodes removed report fewer side effects to the arm and breast than patients who undergo additional lymph node removal.

Breast Density and Hormone Therapy Add to Breast Cancer Risk (08/04/2010)
Postmenopausal women with high breast density are at an increased risk of developing breast cancer, according to the results of a study published in the Journal of Clinical Oncology. This risk increases with the use of hormone therapy.

▪ More...

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Study Explores Risk of Invasive Breast Cancer in Women with DCIS (05/10/2010)
Among women with breast ductal carcinoma in situ (DCIS), evaluation of three molecular markers in a sample of DCIS tissue may provide information about the subsequent risk of invasive breast cancer. These results were published in the Journal of the National Cancer Institute.

Delay in Radiation Therapy Increases Risk of Breast Cancer Recurrence (04/01/2010)
Among older women who undergo breast-conserving surgery (lumpectomy) for early breast cancer, a longer interval between surgery and the start of radiation therapy increases the risk of local cancer recurrence. These results were published in the British Medical Journal.

Acupuncture Reduces Hot Flashes in Breast Cancer Patients (01/04/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.

Young Women with DCIS Have Higher Risk of Recurrence (10/12/2009)
After treatment of breast ductal carcinoma in situ (DCIS) with breast-conserving surgery and radiation therapy, women age 44 or younger have a higher rate of recurrence than older women. These results were presented at the ASCO 2009 Breast Cancer Symposium.

▪ More...

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Tykerb plus Taxol Is Active in Inflammatory Breast Cancer (06/17/2010)
Tykerb® (lapatinib) plus Taxol® (paclitaxel) appears to provide benefit in the initial treatment of inflammatory breast cancer, according to results published in the Journal of Clinical Oncology.

Tykerb® Shows Benefit in Inflammatory Breast Cancer (05/14/2009)
In a Phase II clinical trial, treatment with the targeted therapy Tykerb® (lapatinib) reduced the extent of cancer in 39% of women with HER2-positive, relapsed or refractory inflammatory breast cancer. These results were published in Lancet Oncology.

FDA Approves New Test to Detect HER2 Status in Breast Cancer (07/10/2008)
The U.S. Food and Drug Administration (FDA) has approved a new laboratory test to help identify patients with breast cancer who may benefit from treatment with Herceptin® (trastuzumab).

Tykerb® Effective in Recurrent Inflammatory Breast Cancer (06/06/2008)
Among women with recurrent HER2-positive inflammatory breast cancer (IBC), treatment with Tykerb® (lapatinib) is effective, even among patients whose cancer has progressed following treatment with Herceptin® (trastuzumab). These results were recently reported at the 2008 annual meeting of the American Society of Clinical Oncology.

▪ More...

FDA Advisory Committee Recommends that Avastin No Longer Be Approved for Breast Cancer (07/29/2010)
The Oncology Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) has voted 12 to one that Avastin® (bevacizumab) in combination with paclitaxel should no longer be approved for initial therapy for metastatic HER2-negative breast cancer.

Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (07/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Metastases from Breast Cancer May Differ from Primary Tumor (06/09/2010)
It appears that in metastatic breast cancer, the biologic characteristics of liver metastases sometimes differ from those of the primary tumor. This finding may affect treatment choices for metastases. Results of this retrospective study were presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Herceptin plus Epirubicin and Cyclophosphamide Tolerable and Effective for HER2-positive Metastatic Breast Cancer (04/06/2010)
For women with metastatic, HER2-positive breast cancer, the combination of Herceptin® (trastuzumab) with epirubicin and cyclophosphamide appears to offer a promising treatment option with a relatively low rate of heart complications. These results were published in the Journal of Clinical Oncology.

▪ More...

Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (07/20/2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Eribulin Improves Survival with Metastatic Breast Cancer (06/08/2010)
Among women with previously treated, locally recurrent or metastatic breast cancer, treatment with the investigational chemotherapy drug eribulin mesylate improved overall survival by about 2.5 months. The results of this Phase III clinical trial were presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Optimal Outcomes with Vascular Endothelial Growth Factor (VEGF) (05/28/2010)
An expert panel provided consensus recommendations for appropriate prevention, surveillance and treatment of hypertension (high blood pressure) in patients treated with vascular endothelial growth factor (VEGF) signaling pathway inhibitors. These recommendations were recently published in the Journal of the National Cancer Institute.

Neratinib Active in Women with Advanced HER2-positive Breast Cancer (03/16/2010)
Among women with advanced HER2-positive breast cancer, the investigational drug neratinib produced promising response rates and progression-free survival. The results of this Phase II clinical trial were published in the Journal of Clinical Oncology.

▪ More...

Alcohol Linked with Lobular Breast Cancer (09/03/2010)
Although alcohol is a well-established risk factor for breast cancer, it may be more strongly linked with lobular breast cancer than with ductal breast cancer. These results were published in the Journal of the National Cancer Institute.

Additional Research on Menopausal Hormone Therapy and Breast Cancer (08/24/2010)
A recent study of menopausal hormone therapy and risk of breast cancer reported that risk may vary by body weight and the type of hormone therapy. These results were published in Cancer Epidemiology, Biomarkers, & Prevention.

Mediterranean Diet May Lower Breast Cancer Risk (08/16/2010)
Postmenopausal women who consume a traditional Mediterranean diet may have a lower risk for breast cancer, according to a study published in the American Journal of Clinical Nutrition.

Breast Density and Hormone Therapy Add to Breast Cancer Risk (08/04/2010)
Postmenopausal women with high breast density are at an increased risk of developing breast cancer, according to the results of a study published in the Journal of Clinical Oncology. This risk increases with the use of hormone therapy.

Making Sense of New Mammography Recommendations (07/20/2010)
The U.S. Preventive Services Tasks Force (USPSTF) has reversed its position on screening mammography for women in their 40s: the group no longer recommends routine screening mammography for average-risk women in this age group. The American Cancer Society, however, has stated that it will continue to recommend annual mammograms starting at the age of 40.

▪ More...

Study Evaluates Impact of Lymph Node Removal in Early-stage Breast Cancer (08/13/2010)
Early-stage breast cancer patients without evidence of cancer in their sentinel lymph node who did not have additional lymph nodes removed report fewer side effects to the arm and breast than patients who undergo additional lymph node removal.

Updated Guidelines Address Hormonal Therapy for Breast Cancer (07/21/2010)
Among postmenopausal women with hormone receptor-positive breast cancer, use of an aromatase inhibitor at some point in the course of adjuvant (post-surgery) treatment results in a lower risk of cancer recurrence than use of tamoxifen only.

Many Breast Cancer Patients Taking Adjuvant Hormonal Therapy Stop Treatment Early (07/01/2010)
Less than half of early-stage breast cancer patients with hormone-sensitive disease completed the full dose and schedule of their hormonal therapy treatment. These findings were recently published in the Journal of Clinical Oncology.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Gene Mutation Increases Risk of Blood Clots in Breast Cancer Patients Taking Tamoxifen (06/29/2010)
Among women taking tamoxifen for early-stage breast cancer, an inherited gene mutation (Factor V Leiden) may increase the risk of blood clots.

▪ More...

Study Evaluates Impact of Lymph Node Removal in Early-stage Breast Cancer (08/13/2010)
Early-stage breast cancer patients without evidence of cancer in their sentinel lymph node who did not have additional lymph nodes removed report fewer side effects to the arm and breast than patients who undergo additional lymph node removal.

Many Breast Cancer Patients Taking Adjuvant Hormonal Therapy Stop Treatment Early (07/01/2010)
Less than half of early-stage breast cancer patients with hormone-sensitive disease completed the full dose and schedule of their hormonal therapy treatment. These findings were recently published in the Journal of Clinical Oncology.

Racial Disparity in Breast Cancer Outcomes Among Underinsured (06/30/2010)
Underinsured African-Americans have worse breast cancer survival outcomes than their underinsured White counterparts, according to the results of a study published early online in the Journal of the National Caner Institute.

Gene Mutation Increases Risk of Blood Clots in Breast Cancer Patients Taking Tamoxifen (06/29/2010)
Among women taking tamoxifen for early-stage breast cancer, an inherited gene mutation (Factor V Leiden) may increase the risk of blood clots.

Low Incidence of Heart Complications with Herceptin in Breast Cancer (06/17/2010)
Even with longer-term follow-up, heart problems are not common among breast cancer patients treated with Herceptin® (trastuzumab). These results were published in the Journal of Clinical Oncology.

▪ More...

Exercise and Green Tea May Help Breast Cancer Survivors Beat the Blues (01/28/2010)
Exercising and drinking green tea may help prevent depression among breast cancer survivors, according to the results of a study published in the Journal of Clinical Oncology.

Acupuncture Reduces Hot Flashes in Breast Cancer Patients (01/04/2010)
Among women treated with hormonal therapy for breast cancer, acupuncture and Effexor® (venlafaxine) were similarly effective at reducing the frequency of hot flashes. These results were published in the Journal of Clinical Oncology.

Home Care Nursing Improves Symptom Management (12/04/2009)
Among breast and colorectal cancer patients treated with the oral chemotherapy drug Xeloda® (capecitabine), symptom management was better among patients who received home care nursing than among patients who received standard care. These results were published in the Journal of Clinical Oncology.

Breast Cancer Patients Use Antioxidant Supplements During Treatment (07/15/2009)
Although the consequences of supplementing with antioxidants during cancer treatment remain unknown, many patients with breast cancer continue to use the supplements in an effort to maintain health and diminish the side effects of treatment, according to the results of a study published in Cancer.

Advances in Breast Cancer Treatment 2008 (03/11/2009)
Twenty to 25 percent of breast cancers overexpress (make too much of) a protein known as HER2. Overexpression of this protein leads to increased growth of cancer cells and a worse breast cancer prognosis.

▪ More...